SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 2 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $428,195 | -39.1% | 29,490 | -12.2% | 0.20% | -38.5% |
| Q2 2023 | $702,746 | +30.0% | 33,576 | +31.1% | 0.32% | -26.8% |
| Q1 2023 | $540,756 | +13.9% | 25,604 | +37.2% | 0.44% | +56.0% |
| Q4 2022 | $474,922 | -46.8% | 18,661 | -49.7% | 0.28% | -44.6% |
| Q3 2022 | $892,000 | +6.3% | 37,104 | -3.2% | 0.51% | -23.8% |
| Q4 2021 | $839,000 | -3.8% | 38,347 | -15.9% | 0.67% | +15.8% |
| Q3 2021 | $872,000 | +6.2% | 45,584 | -4.7% | 0.58% | -0.9% |
| Q2 2021 | $821,000 | +5.4% | 47,814 | +37.1% | 0.58% | +0.5% |
| Q1 2021 | $779,000 | – | 34,873 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |